查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870141

癌症影像診斷系統市場按產品類型、應用、技術和最終用戶分類 - 全球預測 2025-2032

Cancer Imaging System Market by Product Type, Application, Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症影像診斷系統市場將成長至 428.1 億美元，複合年成長率為 9.86%。

關鍵市場統計數據
基準年 2024 201.6億美元
預計年份：2025年 221.8億美元
預測年份 2032 428.1億美元
複合年成長率 (%) 9.86%

針對當前癌症影像領域的關鍵挑戰，本文建構了一個全面的框架，重點闡述了診斷準確性、工作流程整合以及臨床領導者應關注的策略投資重點。

現代腫瘤學領域需要兼具診斷準確性和操作效率的影像系統。電腦斷層掃描 (CT)、磁振造影(MRI)、混合成像模式以及人工智慧驅動的工作流程的進步正在改變臨床醫生檢測、分期和後續觀察惡性腫瘤的方式。放射科團隊和醫院管理者在評估影像投資時，不僅關注影像質量，也越來越重視互通性、吞吐量、病患舒適度以及對跨學科診療路徑的後續影響。

觀察影像技術的進步、計算能力的增強以及綜合護理路徑如何重塑腫瘤影像的診斷工作流程和採購理念。

癌症影像領域正經歷一場變革，這場變革由三大並行因素驅動：影像技術創新、運算技術和診療路徑整合。影像技術創新不斷提升CT和MRI平台的空間和時間解析度，而混合系統和檢測器技術的進步則縮短了掃描時間，提高了病灶的可見度。同時，包括人工智慧和3D視覺化工具在內的計算技術正在改善病灶檢測、實現定量測量的自動化以及規範各醫療機構間的報告流程，從而提高診斷的一致性並加快決策速度。

評估關稅主導的採購壓力和供應鏈韌性策略，以重塑診斷影像服務提供者到 2025 年的採購、資金籌措和生命週期規劃。

2025年推出的新關稅措施正在加強對醫療影像生態系統供應鏈的審查，促使採購負責人重新評估零件採購、製造地和整體擁有成本的假設。進口影像零件和資本設備的關稅給採購預算帶來了上行壓力，促使採購者重新評估維護策略、延長設備更新周期，並探索能夠減輕即時資本負擔的替代資金籌措結構。這種財務壓力也促使企業更加重視區域製造和在地化供應鏈網路，以降低跨境貿易政策波動帶來的風險。

透過詳細的細分分析，將產品類型、臨床應用、底層技術和最終用戶優先順序連結起來，以指導模式選擇和服務模式設計。

了解細分市場的細微差別對於使產品選擇和服務模式與臨床和營運目標保持一致至關重要。就產品類型而言，電腦斷層掃描 (CT) 產品涵蓋範圍廣泛，從針對高解析度局部影像最佳化的錐狀射束CT，到用於提高時間解析度的雙源 CT，再到兼顧速度和影像品質的多層螺旋 CT 系統。同時，數位放射線(DR) 選項包括電荷耦合元件 (CCD) 和平板檢測器技術，這些技術會影響劑量效率和工作流程整合。多切面磁振造影(MRI) 提供封閉式系統（優先考慮高場成像以提高診斷準確性）、專用於四肢肌肉骨骼成像的超強 MRI 系統以及旨在提高患者舒適度的開放式 MRI 解決方案。正子斷層掃描 (PET) 的獨特之處在於其 PET-CT 混合系統（整合解剖和代謝數據）以及 PET-MRI 混合系統（將卓越的軟組織對比度與分子成像相結合）。超音波透過多普勒分析進行血管評估，透過2D成像進行常規評估，透過3D或四維分析輔助進行體積評估和手術指導，從而繼續滿足各種臨床需求。

醫療保健結構、法規環境和基礎設施優先事項的差異，導致了不同地區的採用情況和供應商的打入市場策略的差異。

區域趨勢對腫瘤影像領域的普及曲線、供應商策略和服務交付模式有顯著影響。在美洲，注重互通性、清晰的報銷機制和全生命週期服務協議的綜合醫療系統和大型醫院網路正在塑造市場需求。製造商通常會與當地服務供應商建立策略聯盟，以確保運作並協助完成複雜的混合安裝。在歐洲、中東和非洲，不同的法規環境和採購機製造就了不同的普及路徑。這些地區通常呈現出一種平衡：一方面是集中式學術機構推動早期普及，另一方面是分散式診所優先考慮成本效益高的模式和模組化升級。同時，地緣政治因素和基礎設施投資的不均衡可能會加速人們對移動式和可擴展影像解決方案的興趣。

結合卓越的硬體、軟體生態系統以及專注於臨床檢驗和營運連續性的服務模式，實現競爭優勢。

產業相關人員正透過整合卓越的硬體和軟體服務、數據分析以及全面的維護計劃來建立差異化優勢。在傳統成像設備製造商持續投資於檢測器技術、磁鐵設計和混合成像技術的同時，他們也在加速推進人工智慧演算法和視覺化套件的夥伴關係開發和內部研發，以拓展其價值主張，使其超越單純的影像生成。同時，越來越多的專業技術公司正專注於人工智慧驅動的檢測技術、工作流程編排和雲端原生影像管理，這迫使傳統供應商擴展其軟體和服務組合。

供應商和服務商可採取的策略重點：模組化平台、檢驗的人工智慧、靈活的採購方式以及增強的本地服務能力

產業領導者若想更能掌握臨床需求和政策變化，應採取以下幾項相互關聯的策略：首先，優先發展模組化產品架構和軟體可升級平台，使客戶無需更換硬體即可延長系統壽命並引入新的分析功能。其次，投資於經臨床檢驗的人工智慧工具和嚴謹的多中心研究，以證明其在病灶檢測、報告一致性和工作流程效率方面能夠帶來可衡量的改進，從而消除監管障礙並提高採購方的接受度。

採用透明的混合方法，結合相關人員訪談、臨床文獻綜述和技術比較評估，以產生可操作的影像學見解。

本研究整合了一手和二手訊息，以得出循證見解和實用建議。一級資訊來源包括對臨床放射科醫生、影像中心主任、採購負責人和設備服務經理的結構化訪談，以了解操作流程、影像設備優先順序和採購限制。這些定性資訊與技術文獻、同行評審的臨床研究、與監管機構的溝通以及製造商的產品規格進行交叉核對，以確保與當前的臨床證據和設備性能聲明保持一致。

總之，綜合審查強調了將影像能力與臨床路徑結合的重要性、務實的採購方法以及已證實的患者獲益。

隨著癌症治療中早期檢測、精準分期和個人化治療方案的日益普及，診斷影像系統仍然是多學科腫瘤診療流程的核心。先進成像設備、混合成像技術和計算分析的融合正在重塑診斷能力和操作預期。專注於互通性、檢驗的計算工具和靈活服務模式的醫療機構和供應商，將更有能力將技術進步轉化為可衡量的臨床效益。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 人工智慧驅動的影像分析演算法在癌症早期檢測和預後預測的應用日益廣泛
  • 引進整合PET、CT和MRI的多模態影像平台，用於精準腫瘤學工作流程
  • 攜帶式和照護現場影像解決方案的發展使得在資源匱乏地區進行遠端癌症篩檢成為可能；治療性造影劑的出現將分子診斷與靶向放射治療計劃聯繫起來；機器學習模型在臨床環境中用於自動腫瘤分割和體積評估的日益普及；前列腺腫瘤和神經內分泌腫瘤
  • 治療性造影劑的出現將分子診斷與標靶放射治療計劃聯繫起來
  • 在臨床環境中擴大機器學習模型在腫瘤自動分割和體積評估的應用
  • 一種新型PET示蹤劑核准監管部門批准，可增強前列腺癌和神經內分泌腫瘤的檢測。
  • 開發一種混合型PET/MRI掃描儀，可提高軟組織對比度並降低腫瘤影像診斷中的輻射暴露。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 癌症影像診斷系統市場（依產品類型分類）

  • 電腦斷層掃描
    • 錐狀射束CT
    • 雙源CT
    • 多切面CT
  • 數位放射線
    • 電荷耦合元件
    • 平板檢測器
  • 磁振造影
    • 封閉式磁振造影裝置
    • 四肢磁振造影
    • 開放式磁振造影裝置
  • 正子斷層掃描
    • PET CT
    • PET MRI
  • 超音波
    • 多普勒分析
    • 3D/4D 分析
    • 2D分析

第9章 按應用分類的癌症影像診斷系統市場

  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 攝護腺癌

第10章 癌症影像診斷系統市場（依技術分類）

  • 人工智慧
    • 電腦輔助檢測
    • 電腦輔助診斷
    • 工作流程管理
  • 使用造影劑進行診斷影像
    • CT造影劑
    • 磁振造影劑
    • 超音波造影劑
  • 混合成像
    • PET-CT混合
    • PET-MRI混合影像
    • SPECT CT 混合
  • 3D可視化
    • 最大強度投影
    • 表面渲染
    • 體繪製

第11章 癌症影像診斷系統市場（以最終用戶分類）

  • 學術研究機構
  • 診所
  • 診斷影像中心
  • 醫院

第12章 區域癌症影像診斷系統市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 癌症影像診斷系統市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國癌症影像診斷系統市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GE HealthCare Technologies, Inc.
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Canon Medical Systems Corporation
    • Fujifilm Holdings Corporation
    • Hitachi, Ltd.
    • Shimadzu Corporation
    • Konica Minolta, Inc.
    • Samsung Medison Co., Ltd.
    • Hologic, Inc.
Product Code: MRR-3204321AF6C5

The Cancer Imaging System Market is projected to grow by USD 42.81 billion at a CAGR of 9.86% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 20.16 billion
Estimated Year [2025] USD 22.18 billion
Forecast Year [2032] USD 42.81 billion
CAGR (%) 9.86%

Comprehensive framing of current cancer imaging imperatives emphasizing diagnostic precision, workflow integration, and strategic investment priorities for clinical leaders

The contemporary oncology landscape demands imaging systems that combine diagnostic precision with operational efficiency. Advances across computed tomography, magnetic resonance imaging, hybrid modalities, and AI-driven workflows are changing how clinicians detect, stage, and monitor malignancies. Radiology teams and hospital administrators now evaluate imaging investments not solely on image quality but on interoperability, throughput, patient comfort, and downstream impact on multidisciplinary care pathways.

Clinical adoption is being accelerated by tighter integration between imaging modalities and cloud-enabled data management, while value-based care imperatives drive institutions to quantify diagnostic yield and follow-up reductions. At the same time, regulatory scrutiny and reimbursement dynamics influence procurement timelines and capital planning. Therefore, leaders must synthesize technical performance with clinical workflows and fiscal realities when assessing cancer imaging strategies.

This introduction frames the subsequent analysis by focusing on the interplay between modality innovation, technology convergence, and stakeholder requirements. It underscores the necessity for health systems and diagnostic providers to align selection criteria with long-term clinical objectives and operational resilience, and it sets the stage for deeper examination of industry shifts, policy impacts, segmentation insights, and regional dynamics that shape procurement and adoption decisions.

Observing modality advances, computational augmentation, and care pathway integration reshaping diagnostic workflows and procurement philosophies in oncology imaging

The cancer imaging landscape is undergoing transformative shifts driven by three parallel vectors: modality innovation, computational augmentation, and care pathway integration. Modality innovation continues to refine spatial and temporal resolution across CT and MRI platforms while hybrid systems and advances in detector technology reduce scan times and improve lesion conspicuity. Concurrently, computational augmentation through artificial intelligence and three-dimensional visualization tools enhances lesion detection, automates quantitative measurements, and standardizes reporting across sites, thereby improving diagnostic consistency and enabling accelerated decision-making.

Care pathway integration is aligning imaging outputs with multidisciplinary oncology workflows. Radiology reports increasingly feed structured data into tumor boards, surgical planning, and radiation therapy contouring systems. This integration reduces handoff friction and shortens time-to-treatment for complex cases. Additionally, manufacturers and providers are prioritizing patient-centric features such as open-bore MRI designs and faster CT protocols to improve tolerability and throughput, which in turn impacts scheduling efficiency and downstream revenue cycles.

Finally, procurement and service models are shifting toward outcome-oriented contracts and managed equipment services that bundle uptime guarantees, software updates, and AI tool access. These arrangements reflect a broader industry move away from transactional purchasing and toward partnerships that share operational risk and align vendor incentives with clinical outcomes and system efficiency.

Assessment of tariff-driven procurement pressures and supply chain resilience strategies reshaping sourcing, financing, and lifecycle planning across imaging providers in 2025

The introduction of new tariff measures in 2025 has amplified supply chain scrutiny within the medical imaging ecosystem, prompting procurement leaders to evaluate component sourcing, manufacturing footprints, and total cost of ownership assumptions. Tariffs on imported imaging components and capital equipment have placed upward pressure on procurement budgets, encouraging buyers to revisit maintenance strategies, extend equipment refresh cycles, and explore alternative financing structures that mitigate immediate capital strain. This fiscal pressure has also stimulated wider consideration of regional manufacturing and localized supply networks to reduce exposure to cross-border trade policy volatility.

In response, some vendors have accelerated supplier diversification and nearshoring initiatives, relocating critical supply chain nodes closer to major end markets to limit tariff pass-through and shorten lead times. These strategic shifts, however, require substantial lead-time investments and complex qualification of new suppliers to preserve image quality and device safety. Meanwhile, clinical providers have adapted by emphasizing modular upgrades and software-driven performance enhancements that defer full-platform replacement while still delivering incremental clinical benefits.

Regulatory authorities and reimbursement payers have begun assessing whether tariff-induced cost changes necessitate updates to equipment valuation frameworks and procurement guidelines. Hospitals and imaging centers are increasingly negotiating total lifecycle service agreements and consumables bundling to stabilize operational expenses amid pricing uncertainty. As a result, stakeholders are prioritizing resilient procurement strategies, strengthening vendor partnerships, and integrating scenario-based financial planning to preserve access to advanced imaging capabilities while managing near-term cost impacts.

Granular segmentation insights linking product types, clinical applications, enabling technologies, and end user priorities to inform modality selection and service model design

Understanding segmentation nuances is essential for aligning product selection and service models with clinical and operational objectives. When considering product type, computed tomography offerings range from cone beam CT optimized for high-resolution localized imaging to dual source CT that enhances temporal resolution and multi slice CT systems that balance speed and image quality, while digital radiography options include charged coupled device and flat panel detector technologies that affect dose efficiency and workflow integration. Magnetic resonance imaging is available in closed configurations that prioritize high-field diagnostic clarity, extremity MRI systems that deliver focused musculoskeletal imaging, and open MRI solutions that improve patient comfort. Positron emission tomography remains differentiated by PET CT hybrids that merge anatomical and metabolic data and PET MRI hybrids that combine superior soft-tissue contrast with molecular imaging. Ultrasound continues to serve diverse clinical needs through Doppler analysis for vascular assessment, two-dimensional imaging for routine evaluation, and three-dimensional or four-dimensional analyses that support volumetric assessment and procedural guidance.

Applications drive modality prioritization, with specific clinical use cases such as breast cancer screening and diagnostic workup favoring high-resolution mammographic and hybrid solutions, colorectal cancer surveillance requiring cross-sectional imaging and contrast-enhanced techniques, lung cancer pathways depending heavily on low-dose CT protocols and PET-based metabolic characterization, and prostate cancer management leveraging multiparametric MRI and targeted ultrasound interventions. Technology choices further refine value propositions: artificial intelligence supports computer aided detection, computer aided diagnosis, and workflow management that together improve throughput and diagnostic reliability; contrast imaging modalities rely on CT, MRI, and ultrasound agents to enhance lesion delineation and functional assessment; hybrid imaging configurations such as PET CT, PET MRI, and SPECT CT bring complementary diagnostic dimensions; and three-dimensional visualization techniques including maximum intensity projection, surface rendering, and volume rendering facilitate surgical planning and radiotherapy contouring.

End users present distinct procurement and usage patterns. Academic research institutes prioritize extensibility, advanced analytic capabilities, and study-grade data capture. Clinics and diagnostic imaging centers favor throughput, cost-effectiveness, and integrated reporting that streamlines patient throughput. Hospitals require scalable systems that balance acute care demands with outpatient diagnostic volumes and emphasize serviceability and contract support. Recognizing these segmentation layers enables supply-side and clinical leaders to match modality selection and service models to institutional priorities, ensuring investments support diagnostic yield, operational efficiency, and clinical workflow integration.

Regional adoption contrasts and vendor go-to-market adaptations driven by differing healthcare structures, regulatory environments, and infrastructure priorities

Regional dynamics significantly influence adoption curves, vendor strategies, and service delivery models across the cancer imaging landscape. In the Americas, demand is shaped by integrated health systems and large hospital networks that emphasize interoperability, reimbursement clarity, and lifecycle service agreements; manufacturers often pursue strategic partnerships with regional service providers to ensure uptime and to support complex hybrid installations. Europe, the Middle East & Africa features heterogeneous regulatory environments and procurement mechanisms that create varied adoption pathways; this region commonly balances centralized academic centers driving early adoption with decentralized clinics prioritizing cost-effective modalities and modular upgrades, while geopolitical factors and uneven infrastructure investment can accelerate interest in mobile and scalable imaging solutions.

Asia-Pacific continues to exhibit rapid investment in capacity expansion and technology adoption driven by population-scale screening programs and growing cancer care networks, leading to a diverse landscape where high-volume urban centers adopt cutting-edge hybrid and AI-enabled systems while secondary markets prioritize robust, easy-to-service platforms. Vendors respond by tailoring go-to-market approaches and financing models to regional needs, offering managed service options, training programs, and localized support hubs. These regional contrasts influence product development roadmaps and aftermarket strategies, encouraging vendors to design platforms that balance global technical standards with configurable deployment options for distinct regulatory and clinical contexts.

Competitive differentiation through combined hardware excellence, software ecosystems, and service models that prioritize clinical validation and operational continuity

Industry participants are increasingly differentiating through integrated ecosystems that combine hardware excellence with software services, data analytics, and comprehensive maintenance programs. Established imaging manufacturers continue to invest in detector technologies, magnet design, and hybrid modality engineering while also accelerating partnerships and in-house development of AI algorithms and visualization suites to extend value beyond raw image generation. Concurrently, a growing cohort of specialist technology firms focuses on AI-enabled detection, workflow orchestration, and cloud-native image management, pressuring traditional vendors to broaden their software and service portfolios.

Strategic activity includes partnerships for clinical validation, regulatory submissions for AI tools, and the expansion of service footprints to support complex hybrid installations and bundled consumables. Competitive positioning increasingly depends on demonstrating clinical utility through peer-reviewed evidence and cross-site validation studies that show reproducible improvements in diagnostic accuracy and workflow efficiency. Additionally, vendors that offer flexible financing, comprehensive training, and outcome-linked service agreements gain traction among large health systems seeking to align vendor incentives with clinical performance and operational uptime.

Actionable strategic priorities for vendors and providers focusing on modular platforms, validated AI, flexible procurement, and resilient regional service capabilities

Industry leaders can act decisively to capitalize on clinical demand and policy shifts by pursuing several interlocking strategies. First, prioritize modular product architectures and software-upgradeable platforms that allow customers to extend system life and adopt new analytic capabilities without full hardware replacement. Second, invest in clinically validated AI tools and rigorous multi-center studies that demonstrate measurable improvements in lesion detection, reporting consistency, and workflow efficiency, thereby smoothing regulatory pathways and buyer acceptance.

Third, develop flexible procurement options including managed service agreements, subscription licensing, and outcome-linked contracts that align vendor revenue models with customer operational goals. Fourth, strengthen regional service networks and spare-part ecosystems to mitigate tariff and supply chain risk, and consider nearshoring critical component manufacturing where feasible to stabilize lead times and costs. Fifth, design training and implementation programs that embed imaging outputs into multidisciplinary care pathways, ensuring that new capabilities translate into faster clinical decisions and measurable patient benefit. Executing these priorities will require cross-functional coordination among R&D, regulatory affairs, commercial teams, and clinical partners to deliver cohesive product and service propositions that meet the evolving needs of oncologic care providers.

Transparent mixed-methods approach combining stakeholder interviews, clinical literature review, and comparative technology assessments to produce actionable imaging insights

This research synthesized primary and secondary intelligence to produce evidence-based insights and practical recommendations. Primary inputs included structured interviews with clinical radiologists, imaging center directors, procurement officers, and device service managers to capture operational realities, modality priorities, and procurement constraints. These qualitative inputs were triangulated with technical literature, peer-reviewed clinical studies, regulatory communications, and manufacturer product specifications to ensure alignment with current clinical evidence and device performance claims.

Analytical methods combined thematic analysis of stakeholder interviews with comparative technology assessment frameworks that evaluate image quality, throughput, serviceability, and software integration potential. Supply chain and policy impacts were assessed through scenario planning that considered tariff changes, supplier diversification efforts, and regional manufacturing shifts. Throughout, emphasis remained on verifiable clinical and operational outcomes rather than speculative forecasts, and recommendations were calibrated to align with typical procurement cycles and capital planning horizons across hospital systems and diagnostic providers.

Concluding synthesis emphasizing the necessity of aligning imaging capabilities with clinical pathways, procurement pragmatism, and demonstrated patient benefit

As cancer care increasingly prioritizes early detection, precision staging, and personalized treatment planning, imaging systems will remain central to multidisciplinary oncology pathways. The convergence of advanced modality hardware, hybrid imaging techniques, and computational analytics is reshaping diagnostic capabilities and operational expectations. Providers and vendors who focus on interoperability, validated computational tools, and flexible service models will be best positioned to translate technological advances into measurable clinical gains.

Policy and procurement environments will continue to influence adoption patterns, making supply chain resilience and financing flexibility critical considerations for sustained access to advanced imaging. Ultimately, success will hinge on aligning product capabilities with clinical workflows and outcome metrics, thereby ensuring that investments in imaging technology directly support improved patient pathways and system efficiency. Stakeholders should treat imaging strategy as an integral component of broader oncology program development rather than as an isolated capital decision.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of AI-driven image analysis algorithms for early cancer detection and prognosis
  • 5.2. Integration of multimodal imaging platforms combining PET, CT and MRI for precision oncology workflows
  • 5.3. Growth in portable and point-of-care imaging solutions enabling remote cancer screening in low resource settings
  • 5.4. Emergence of theranostic imaging agents linking molecular diagnostics with targeted radiotherapy planning
  • 5.5. Increasing use of machine learning models for automated tumor segmentation and volumetric assessment in clinical practice
  • 5.6. Regulatory approvals of novel PET tracers enhancing detection of prostate and neuroendocrine tumors
  • 5.7. Development of hybrid PET/MRI scanners improving soft tissue contrast and reducing radiation exposure in oncologic imaging

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Imaging System Market, by Product Type

  • 8.1. Computed Tomography
    • 8.1.1. Cone Beam Computed Tomography
    • 8.1.2. Dual Source Computed Tomography
    • 8.1.3. Multi Slice Computed Tomography
  • 8.2. Digital Radiography
    • 8.2.1. Charged Coupled Device
    • 8.2.2. Flat Panel Detector
  • 8.3. Magnetic Resonance Imaging
    • 8.3.1. Closed Magnetic Resonance Imaging
    • 8.3.2. Extremity Magnetic Resonance Imaging
    • 8.3.3. Open Magnetic Resonance Imaging
  • 8.4. Positron Emission Tomography
    • 8.4.1. PET CT
    • 8.4.2. PET MRI
  • 8.5. Ultrasound
    • 8.5.1. Doppler Analysis
    • 8.5.2. Three D Four D Analysis
    • 8.5.3. Two D Analysis

9. Cancer Imaging System Market, by Application

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Lung Cancer
  • 9.4. Prostate Cancer

10. Cancer Imaging System Market, by Technology

  • 10.1. Artificial Intelligence
    • 10.1.1. Computer Aided Detection
    • 10.1.2. Computer Aided Diagnosis
    • 10.1.3. Workflow Management
  • 10.2. Contrast Imaging
    • 10.2.1. CT Contrast Agents
    • 10.2.2. MRI Contrast Agents
    • 10.2.3. Ultrasound Contrast Agents
  • 10.3. Hybrid Imaging
    • 10.3.1. PET CT Hybrid
    • 10.3.2. PET MRI Hybrid
    • 10.3.3. SPECT CT Hybrid
  • 10.4. Three D Visualization
    • 10.4.1. Max Intensity Projection
    • 10.4.2. Surface Rendering
    • 10.4.3. Volume Rendering

11. Cancer Imaging System Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Clinics
  • 11.3. Diagnostic Imaging Centers
  • 11.4. Hospitals

12. Cancer Imaging System Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer Imaging System Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Imaging System Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. GE HealthCare Technologies, Inc.
    • 15.3.2. Siemens Healthineers AG
    • 15.3.3. Koninklijke Philips N.V.
    • 15.3.4. Canon Medical Systems Corporation
    • 15.3.5. Fujifilm Holdings Corporation
    • 15.3.6. Hitachi, Ltd.
    • 15.3.7. Shimadzu Corporation
    • 15.3.8. Konica Minolta, Inc.
    • 15.3.9. Samsung Medison Co., Ltd.
    • 15.3.10. Hologic, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CANCER IMAGING SYSTEM MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CANCER IMAGING SYSTEM MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER IMAGING SYSTEM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS CANC